Friday, August 12, 2022
No menu items!

Amryt Pharma reports record quarterly sales.

Must Read

Amryt Pharma announces record-breaking revenue for the most recent quarter.

Amryt Pharma said today that it had begun a share buyback program and recorded record sales for the second quarter ending June 30th.

According to the company’s financials, sales for the first half of the year were 9.2% higher than the same time in the previous year, bringing total revenue to $68.5 million.

Prior to financing charges, Amryt’s second-quarter operational loss was $6.9 million, compared to a $4.1 million operating loss in the same period of the preceding year.

Chiasma restructuring and acquisition costs were excluded from the $13.3 million in EBITDA, which resulted in an EBITDA before restructuring and acquisition costs of $13.3 million.

E.C. approval of Filsuvez for EB patients six months or older was granted by the European Commission during this quarter.

An Amryt spokesman said this clearance was a key milestone in the company’s history and a substantial boost for European patients with the debilitating ailment.

By excluding the impact of a single LATAM order placed in the second quarter of 2013, Methyleptin’s sales climbed 49.9 percent year over year in the second quarter.


Please enter your comment!
Please enter your name here

Latest News

Scarlet and Violet Might Reintroduce a Contentious Pokemon Feature.

The disputed Sword and Shield feature will reportedly return in Pokemon Scarlet and Violet, according to rumors. Even among those...

More Articles Like This